Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 323

Results For "EIR"

3316 News Found

NPPA has put a cap on the trade margin of 42 select non-scheduled anti-cancer medicines
Policy | August 11, 2021

NPPA has put a cap on the trade margin of 42 select non-scheduled anti-cancer medicines

A total of 526 brands has seen a reduction of up to 90 per cent in MRP


ALS drug RADICAVA holds promise as it completes four years in US
News | August 10, 2021

ALS drug RADICAVA holds promise as it completes four years in US

Nearly 6,000 patients have been treated with the drug since 2017


QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements
Drug Approval | August 10, 2021

QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements

QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab


Union Minister Sonowal promises AIIA of establishing a Bio-bank in Ayurveda
Events | August 09, 2021

Union Minister Sonowal promises AIIA of establishing a Bio-bank in Ayurveda

All India Institute of Ayurveda hosts ministers and showcase their achievements


Govt. to open 10,500 Janaushadhi Kendras: Mandaviya
Healthcare | August 09, 2021

Govt. to open 10,500 Janaushadhi Kendras: Mandaviya

The government has recently enhanced the incentive granted to storeowners from existing Rs. 2.50 lakh to Rs. 5.00 lakh given at the rate of 15% of monthly purchases made, subject to a ceiling of Rs. 15,000 per month


TAKE divests stake in Navitas Life Sciences to HIG
Biotech | August 08, 2021

TAKE divests stake in Navitas Life Sciences to HIG

The transaction is expected to close in the Q4FY22


We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
interviews | August 07, 2021

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.


SPI Pharma partners Azelis Americas
Supply Chain | August 07, 2021

SPI Pharma partners Azelis Americas

In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace


Stelis Biopharma appoints Mark W. Womack as CEO
People | August 07, 2021

Stelis Biopharma appoints Mark W. Womack as CEO

He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations


Mark W. Womack is the new CEO of Stelis Biopharma
Biotech | August 06, 2021

Mark W. Womack is the new CEO of Stelis Biopharma

He will be stationed at the company HQ in Bengaluru, India